Jane Street’s Protagonist Therapeutics PTGX Stock Holding History

Jane Street’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$282K	Buy	+2,300	New	+$240K	﹤0.01%	9354
2025 Q3	–	Sell	-8,800	Closed	-$486K	–	11560
2025 Q2	$486K	Sell	8,800 -42,000	-83%	-$2.02M	﹤0.01%	6970
2025 Q1	$2.46M	Buy	50,800 +39,900	+366%	+$1.67M	﹤0.01%	4043
2024 Q4	$421K	Buy	+10,900	New	+$475K	﹤0.01%	7147
2024 Q3	–	Sell	-42,800	Closed	-$1.48M	–	10246
2024 Q2	$1.48M	Sell	42,800 -20,000	-32%	-$586K	﹤0.01%	5033
2024 Q1	$1.82M	Buy	+62,800	New	+$1.71M	﹤0.01%	4302
2023 Q3	–	Sell	-18,300	Closed	-$505K	–	9219
2023 Q2	$505K	Sell	18,300 -9,700	-35%	-$243K	﹤0.01%	6307
2023 Q1	$644K	Buy	+28,000	New	+$470K	﹤0.01%	5878
2022 Q3	–	Sell	-57,800	Closed	-$457K	–	10292
2022 Q2	$457K	Buy	57,800 +27,100	+88%	+$328K	﹤0.01%	6903
2022 Q1	$727K	Buy	+30,700	New	+$865K	﹤0.01%	6774

Other funds holding PTGX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Jane Street's PTGX Position: Q2 2026 in Review

Jane Street increased its Protagonist Therapeutics (PTGX) stake by 368% in Q2 2026, buying an estimated $1.39M and bringing the position to 16,882 shares worth $2.07M. The position accounts for ﹤0.01% of the portfolio, ranked #5106.

Jane Street first reported a position in PTGX in Q3 2016 and has held it in 22 quarters since. The position peaked at $9.35M in Q1 2025. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

Jane Street held 16,882 shares of Protagonist Therapeutics worth $2.07M as of Q2 2026.
Jane Street bought 13,275 Protagonist Therapeutics shares in Q2 2026, an estimated $1.39M.
Protagonist Therapeutics made up ﹤0.01% of Jane Street's portfolio in Q2 2026, its #5106 holding.
Jane Street first reported a position in Protagonist Therapeutics in Q3 2016 and has held it in 22 quarters since.
Jane Street's Protagonist Therapeutics position peaked at $9.35M in Q1 2025.
343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.